Novavax (NVAX) Stock Price, News & Analysis

Company Overview

Novavax, Inc. is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland. In addition to its COVID-19 vaccine, the company has pursued vaccine candidates for other infectious diseases, including influenza and respiratory syncytial virus, and may seek to advance products through partnerships and collaborations. John C. Jacobs serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $8.95 to $9.58
• 50-Day Range: $7.93 to $12.82
• 52-Week Range: $6.20 to $13.39
• Volume: 2.04 million shs
• Average Volume: 5.20 million shs
• Market Capitalization: $1.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.33
• Consensus Rating: Hold

Novavax Stock Analysis - MarketRank™

Novavax scored higher than 44% of companies evaluated by MarketBeat, and ranked 409th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Novavax has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 3 sell ratings.

Upside Potential

Novavax has a consensus price target of $12.33, representing about 33.3% upside from its current price of $9.26.

Amount of Analyst Coverage

Novavax has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Novavax are expected to grow in the coming year, from ($0.38) to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novavax is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novavax is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.17% of the float of Novavax has been sold short.

Short Interest Ratio / Days to Cover

Novavax has a short interest ratio ("days to cover") of 4.34.

Change versus previous month

Short interest in Novavax has recently increased by 2.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novavax does not currently pay a dividend.

Dividend Growth

Novavax does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

Novavax has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Novavax this week, compared to 8 articles on an average week.

Search Interest

51 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 59% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novavax insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Novavax is held by insiders.

Percentage Held by Institutions

53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVAX
• CIK: 1000694
• Web: www.novavax.com
• Phone: (240) 268-2000
• Fax: 240-268-2100
• Employees: 749
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Novavax: $12.33
• High Price Target: $19.00
• Low Price Target: $6.00
• Potential Upside/Downside: +29.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $440.30 million
• Net Margins: -59.87%
• Pretax Margin: -59.28%
• Return on Equity: -14.82%
• Return on Assets: -13.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 1.40
• Cash Flow: $3.45 per share
• Price / Cash Flow: 2.76
• Book Value: ($0.79) per share
• Price / Book: -12.06

Miscellaneous

• Outstanding Shares: 164,950,000
• Free Float: 162,307,000
• Market Cap: $1.57 billion
• Optionable: Optionable
• Beta: 2.44